Navigation Links
PAREXEL Experts to Present Advanced Approaches to Accelerate Development, Maximize Product Value at DIA EuroMeeting
Date:3/7/2011

BOSTON, March 7, 2011 /PRNewswire/ -- Through various presentations to be delivered at the Drug Information Association (DIA) 23rd Annual EuroMeeting, being held March 28-30, 2011 in Geneva, Switzerland, experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will address advanced approaches to help the biopharmaceutical industry meet demands of a changing global marketplace.

Experts from PAREXEL will be available at Stands 1050, 1052, 1151, and 1153 in the exhibit hall to discuss how the Company can help biopharmaceutical companies improve early-stage decisions, accelerate pivotal trials, reach new markets, and leverage technologies for increased operational quality and efficiency.  PAREXEL experts will discuss new operational models, supported by technology, to help its clients achieve greater benefits and speed development.

The DIA EuroMeeting program features the following presentations by PAREXEL experts, which address the benefits of combined clinical and technology expertise to enable more effective information flow and improved data access for greater visibility into trials – and ultimately, better decision making:

Tuesday, March 29

  • Session 1, 9:00: Use of Electronic Health Records for Clinical Research, Isabelle de Zegher, Worldwide Senior Director Technology Integration and Data Standards

  • Wednesday, March 30

  • Session 5, 9:00: How to Go Effectively from Data Collection in CDASH to Submission in SDTM: The need for an eCRF library, Isabelle de Zegher, Worldwide Senior Director Technology Integration & Data Standards
  • Session 6, 11:00: Using Technology to Improve the Clinical Trial Process, Liz Love, Product Manager
  • Session 8, 16:00: Simplicity (for sites) is the Ultim
    '/>"/>

  • SOURCE PAREXEL International Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
    2. PAREXEL Expands Global Clinical Pharmacology Capabilities
    3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
    4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
    5. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
    6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
    7. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
    8. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
    9. PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
    10. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
    11. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
    (Date:8/28/2015)... , August 28, 2015 The scientific ... collaboration with one of the leading academics in the field ... world record holder in life extension for model animals - ... biology of aging and age-related diseases, primarily, around the stability ... has just been published as "Stability analysis of a model ...
    (Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
    Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
    ... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... company at the Bank of America Merrill Lynch Healthcare conference in ... Las Vegas, NV Presentation date: Tuesday May 10, 2011 ... A live webcast and 30-day archive of this presentation ...
    ... MELVILLE, N.Y., May 3, 2011 Henry Schein, ... healthcare products and services to office-based practitioners, today reported record ... Net sales for the first quarter of 2011 were ... quarter of 2010.  This consists of 9.9% growth in local ...
    Cached Medicine Technology:Henry Schein Reports Record First Quarter Results 2Henry Schein Reports Record First Quarter Results 3Henry Schein Reports Record First Quarter Results 4Henry Schein Reports Record First Quarter Results 5Henry Schein Reports Record First Quarter Results 6Henry Schein Reports Record First Quarter Results 7Henry Schein Reports Record First Quarter Results 8Henry Schein Reports Record First Quarter Results 9
    (Date:8/29/2015)... AZ (PRWEB) , ... August 30, 2015 , ... ... David O’Shea to serve as the college’s Vice President of Strategic Initiatives and Information ... is eager to help the college expand its reach and impact through innovative technologies ...
    (Date:8/29/2015)... ... 29, 2015 , ... "I have been a licensed physical ... specialize in manual therapy, and my invention will provide headache sufferers a solution ... muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, ...
    (Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , ... standard shipping costs. , “Before, a threshold of $49.00 was required to qualify for ... items qualify for free standard shipping for customers regardless of the item’s selling price.” ...
    (Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
    (Date:8/28/2015)... Sierra Madre, CA (PRWEB) , ... August 28, ... ... alternative solutions to wound center management, Decatur County Memorial Hospital recently transitioned management ... model of Wound Center Management for their outpatient wound center. , ...
    Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
    ... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), a ... products, today,announced that it has entered into definitive ... of 8,750,000 shares of,its common stock at $2.40 ... purchase 3,500,000 shares of common stock at an,exercise ...
    ... Respectively, Over Prior Year ... Period-, EXTON, Pa., ... for its second quarter and six,months of fiscal year 2008., Second Quarter ... income, increased 14% to $19.6 million in the Company,s second,fiscal quarter ended December ...
    ... Matthew L. Myers ... Tobacco-Free Kids, WASHINGTON, Jan. 24 The following statement,was ... A new global survey released by the U.S. Centers ... use, and even higher,rates of exposure to secondhand smoke, among ...
    ... 24 Karen Ignagni, President,and CEO of ... statement on,the Institute of Medicine,s (IOM) recommendation ... the effectiveness of healthcare products and,services:, ... deserve to know not only what medical ...
    ... day low price philosophy helps customers save more ... compared to prescription retail price, BENTONVILLE, Ark., ... recent prescription to over-the-counter (OTC) approved,drug, Zyrtec(R) (cetirizine ... Wal-Mart will offer eight different OTC Zyrtec products, ...
    ... Department of,Health and Human Services (HHS) Secretary ... standards developed by the Healthcare Information,Technology Standards ... advanced three,of its "Interoperability Specifications" to help ... a Nationwide Health Information Network in,the United ...
    Cached Medicine News:Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 2Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 3Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 4Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 2Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 3Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 4Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 5Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 6Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 7Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 8Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 9Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 10Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 11Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 12Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 13Health News:New CDC Global Survey Finds Tobacco Taking Massive Toll on World's Children 2Health News:New CDC Global Survey Finds Tobacco Taking Massive Toll on World's Children 3Health News:Wal-Mart Becomes One of the First to Offer Over-the-Counter Zyrtec 2Health News:Wal-Mart Becomes One of the First to Offer Over-the-Counter Zyrtec 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 2Health News:HHS Secretary Recognizes Products of HITSP Standards Work 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 4
    Colloidal Gold Conjugated, Protein A - 12 OD...
    Colloidal Gold Conjugated, Protein G - 12 OD...
    Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
    Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
    Medicine Products: